BRAF inhibitors in metastatic non-small cell lung cancer

Affiliations

Editorial

Geòrgia Anguera et al. J Thorac Dis. 2018 Feb.

. 2018 Feb;10(2):589-592.

doi: 10.21037/jtd.2018.01.129.

¹ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Dabrafenib plus trametinib in patients with previously untreated BRAF^V600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.
Planchard D, Smit EF, Groen HJM, Mazieres J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P, Mookerjee B, Johnson BE. Planchard D, et al. Lancet Oncol. 2017 Oct;18(10):1307-1316. doi: 10.1016/S1470-2045(17)30679-4. Epub 2017 Sep 11. Lancet Oncol. 2017. PMID: 28919011 Clinical Trial.

1. Torre LA, Siegel RL, Jemal A, et al. Lung Cancer Statistics. Adv Exp Med Biol 2016;893:1-19. 10.1007/978-3-319-24223-1_1 - DOI - PubMed
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer Incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403. 10.1016/j.ejca.2012.12.027 - DOI - PubMed
1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. Bethesda: National Cancer Institute. Available online: http://seer.cancer.gov/csr/1975_2012/
1. Scagliotti GV, Parikh P, von Pawel J. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer. J Clin Oncol 2008;26:3543-51. 10.1200/JCO.2007.15.0375 - DOI - PubMed
1. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer. J Clin Oncol 2013;31:2895-902. 10.1200/JCO.2012.47.1102 - DOI - PubMed